Baidu
map

Nat Commun:港大化学系成功合成当下厉害的抗生素Teixobactin

2016-08-31 韩琨 科学网

近日,记者从香港大学处获悉,由香港大学化学系副教授李学臣团队及其在美国佛罗里达大学和香港理工大学的合作伙伴在国际学术期刊《自然通讯》(Nature Communications)共同发表了有关新型抗生素Teixobactin的合成研究结果。 Teixobactin是近30年来被发现的第一种新型抗生素。它的化学合成也为新一代抗生素的应用与发展奠定了化学基础。过去七年来,李学臣及其研究团队一直致力研发

由香港大学化学系副教授李学臣团队及其在美国佛罗里达大学和香港理工大学的合作伙伴在国际学术期刊《自然通讯》(Nature Communications)共同发表了有关新型抗生素Teixobactin的合成研究结果。 Teixobactin是近30年来被发现的第一种新型抗生素。它的化学合成也为新一代抗生素的应用与发展奠定了化学基础。(美研发新型抗生素teixobactin )

过去七年来,李学臣及其研究团队一直致力研发新型抗生素。2013年间,他们首次利用化学方法全合成了达托霉素,并以此为基础,开展了新一代达托霉素类抗菌药物的研发工作。最近,李学臣团队再次用化学合成的方法,成功合成了热门抗菌化合物Teixobactin。

新型抗生素Teixobactin于2015年被美国科学家所发现,实现了抗菌药物领域上的巨大突破,可以杀死耐甲氧西林金黄色葡萄球菌(MRSA)、万古霉素耐药肠球菌(VRE)、结核分枝杆菌等多种致命病原体,最关键的是,Teixobactin不会诱发细菌耐药性的产生。化学合成是唯一可以通过简单的原料灵活修饰化学结构并得到大量teixobactin衍生物的方法。因此,Teixobactin的化学合成引起了世界各地多个研究团队的密切关注和激烈竞争。通过与美国中佛罗里达大学的一个化学实验室合作,李学臣的研究小组成为全球最先成功开发Teixobactin合成路线的实验室之一。基于他们研发的合成方法,研究团队已经合成了10款具有应用前景的Texobactin类似物(已申请美国临时专利),他们所研究的合成途径可以快速并有效地合成多种Teixobactin的衍生物。未来两年间,他们将致力合成100种不同的Teixobactin衍生物,以提高其药效并应用于临床研究。

不过,在6月份,另外一个团队也人工合成了Teixobactin抗生素。

原始出处:

Jin K, Sam IH, Po KH, Lin D, Ghazvini Zadeh EH, Chen S, Yuan Y, Li X. Total synthesis of teixobactin. Nat Commun. 2016 Aug 3;7:12394. doi: 10.1038/ncomms12394.


Giltrap AM, Dowman LJ, Nagalingam G, Ochoa JL, Linington RG, Britton WJ, Payne RJ. Total Synthesis of Teixobactin. Org Lett. 2016 Jun 3;18(11):2788-91.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035957, encodeId=1728203595e60, content=<a href='/topic/show?id=8c551e2591d' target=_blank style='color:#2F92EE;'>#teixobactin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17259, encryptionId=8c551e2591d, topicName=teixobactin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Jul 14 07:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881293, encodeId=f0be1881293d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 02 04:45:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086898, encodeId=5410208689805, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 26 22:45:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130414, encodeId=24e5130414b7, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:57:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108933, encodeId=7ade1089332c, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:11:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035957, encodeId=1728203595e60, content=<a href='/topic/show?id=8c551e2591d' target=_blank style='color:#2F92EE;'>#teixobactin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17259, encryptionId=8c551e2591d, topicName=teixobactin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Jul 14 07:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881293, encodeId=f0be1881293d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 02 04:45:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086898, encodeId=5410208689805, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 26 22:45:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130414, encodeId=24e5130414b7, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:57:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108933, encodeId=7ade1089332c, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:11:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
    2017-02-02 仁心济世
  3. [GetPortalCommentsPageByObjectIdResponse(id=2035957, encodeId=1728203595e60, content=<a href='/topic/show?id=8c551e2591d' target=_blank style='color:#2F92EE;'>#teixobactin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17259, encryptionId=8c551e2591d, topicName=teixobactin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Jul 14 07:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881293, encodeId=f0be1881293d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 02 04:45:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086898, encodeId=5410208689805, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 26 22:45:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130414, encodeId=24e5130414b7, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:57:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108933, encodeId=7ade1089332c, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:11:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
    2017-01-26 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=2035957, encodeId=1728203595e60, content=<a href='/topic/show?id=8c551e2591d' target=_blank style='color:#2F92EE;'>#teixobactin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17259, encryptionId=8c551e2591d, topicName=teixobactin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Jul 14 07:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881293, encodeId=f0be1881293d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 02 04:45:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086898, encodeId=5410208689805, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 26 22:45:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130414, encodeId=24e5130414b7, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:57:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108933, encodeId=7ade1089332c, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:11:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
    2016-09-18 ylzr123

    好文,从这里学习了好多新知识,新信息。赞了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2035957, encodeId=1728203595e60, content=<a href='/topic/show?id=8c551e2591d' target=_blank style='color:#2F92EE;'>#teixobactin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17259, encryptionId=8c551e2591d, topicName=teixobactin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Jul 14 07:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881293, encodeId=f0be1881293d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 02 04:45:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086898, encodeId=5410208689805, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 26 22:45:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130414, encodeId=24e5130414b7, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:57:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108933, encodeId=7ade1089332c, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:11:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
    2016-09-01 Guoxj3234

    学习起来

    0

相关资讯

Nat Microbiol:澳大利亚科学家开发出治疗军团菌病新型药物

(图片摘自www.eurekalert.org) 科学家们最近开发出一类新型药物可以有效治疗军团菌感染引发的严重肺病。 该药物不仅能够有效治疗军团菌感染的疾病,还能够应用于其它细菌感染的疾病,包括那些对抗生素极度耐受的细菌。 这一研究的主要作者是来自澳大利亚Walter and Eliza Hall研究所的James Vince博士以及来自Monash大学的Thomas Naderer博

《中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2016年版)》发布

中性粒细胞缺乏伴发热患者是一组特殊的疾病人群。由于免疫功能低下,炎症的症状和体征常不明显,病原菌及感染灶也不明确,发热可能是感染的唯一征象,如没有给予及时恰当的抗菌药物治疗,感染相关死亡率高。因此,充分认识中性粒细胞缺乏伴发热患者的相关风险、诊断方法以及如何合理使用抗菌药物,对于降低中性粒细胞缺乏伴发热的发生和病死风险至关重要。参考国际指南并结合国内流行病学资料、细菌耐药检测数据以及抗菌药物临床应

我国《抗菌药物临床应用管理办法》施行

昨天(8月1日),被称为“史上最严限抗令”的《抗菌药物临床应用管理办法》(以下简称《办法》)开始实施,以安全性、有效性、细菌耐药情况和价格因素4个方面为基本原则,该文件将抗菌药物分为非限制使用、限制使用与特殊使用三级管理。其中明确规定了不同等级医生的开药权限。严重违规使用抗菌药物的医生将被吊销执业证书。   □规定发布   医师开药资格将受限   根据《办

住院患者使用抗生素禁超55% 医生禁开大处方

记者15日从我市卫生部门获悉,为了保障市民用药安全,我市综合医院住院患者抗菌药物使用率将控制在55%以内,门诊患者抗菌药物处方比例控制在15%以内,急诊患者抗菌药物处方比例控制在35%以内,抗菌药物使用强度力争控制在每百人天40DDDs以下。 感冒发烧慎用抗生素 市民黄蕾觉得最近身体不太舒服,她妈妈让她吃点抗生素,预防一下感染。据了解,很多市民像黄蕾的妈妈一样,存在滥用抗生素

NAT CHEM BIOL:科学家发现新的细菌通讯“语言”

发光杆菌显微镜图像。标为红色的细胞产生聚集因子 自然界中,细菌并不独居,而是和其它细菌形成群体生活。它们通过化学过程相互沟通,不仅能感应到其它细菌群体的存在,甚至彼此能建立合作网络。慕尼黑大学的研究人员对一种以前未知的细菌通信方式首次做出了解释,研究结果对医药研究有积极的推动。 慕尼黑大学的微生物学家黑尔曼(Ralf Heermann)博士和法兰克福歌德大学波德(Helge Bode)教授

CDSR:普通感冒无需使用抗菌药物

题目:抗菌药物治疗普通感冒和急性化脓性鼻炎(Antibiotics for the common cold and acute purulent rhinitis) 背景:长久以来,一直认为抗菌药物对一般感冒无效,但考虑到抗菌药物可能会预防继发的细菌感染,因此仍然经常处方抗菌药物。【原文下载】 目的:确定与

Baidu
map
Baidu
map
Baidu
map